Tamoxifen Concept

subject area of

• neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II  Academic Article
• A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen  Academic Article
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer  Academic Article
• A Trial of Two Questions  Academic Article
• A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis  Academic Article
• A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen  Academic Article
• A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1  Academic Article
• A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)  Academic Article
• A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.  Academic Article
• A review of exemestane in the management of breast cancer  Academic Article
• A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer  Academic Article
• Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study  Academic Article
• Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer  Conference Paper
• Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations  Academic Article
• Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis  Academic Article
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial  Academic Article
• Adjuvant endocrine therapies for pre-/perimenopausal women  Academic Article
• Adjuvant endocrine therapy for breast cancer: a commentary.  Academic Article
• Adjuvant endocrine therapy of breast cancer  Academic Article
• Adjuvant therapy of the very young woman  Conference Paper
• American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction  Academic Article
• American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002  Academic Article
• An Integrated Approach to Male-Factor Subfertility: Bridging the Gap Between Fertility Specialists Trained in Urology and Gynaecology  Academic Article
• An aromatase inhibitor and tamoxifen decrease plasma levels of o,p′-DDT and its metabolites in Nile tilapia (Oreochromis niloticus)  Academic Article
• An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer  Academic Article
• Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data  Conference Paper
• Antihormone Therapy in Recurrent Metastatic Breast Cancer  Academic Article
• Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen  Academic Article
• Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review  Academic Article
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials  Academic Article
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials  Academic Article
• Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women  Academic Article
• Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial  Academic Article
• Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study  Academic Article
• Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer  Academic Article
• Asymptomatic Atypical Hyperplasia and Endometriosis Following Treatment with Tamoxifen: A Case Report and Review of the Literature  Academic Article
• Asymptomatic Endometrial Thickening  Academic Article
• Breast Cancer Prevention with Selective Estrogen Receptor Modulators  Academic Article
• CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned  Academic Article
• Cardiovascular Health and Aromatase Inhibitors  Academic Article
• Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.  Academic Article
• Chemoprevention: Drug pricing and mortality  Academic Article
• Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer  Academic Article
• Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer  Academic Article
• Clomiphene or tamoxifen for idiopathic oligo/asthenospermia  Academic Article
• Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.  Academic Article
• Current and future directions in medical therapy for breast carcinoma  Academic Article
• Current status of adjuvant endocrine therapy for resectable breast cancer.  Academic Article
• Developmental changes in the gonadotropin releasing hormone neuron of the female rabbit: effects of tamoxifen citrate and pregnant mare serum gonadotropin  Academic Article
• Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer  Conference Paper
• Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?  Academic Article
• Droloxifene, a new antiestrogen: Its role in metastatic breast cancer  Academic Article
• Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial  Academic Article
• Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers  Academic Article
• Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17  Academic Article
• Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials  Academic Article
• Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer  Academic Article
• Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93  Academic Article
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials  Academic Article
• Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17  Conference Paper
• Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17  Academic Article
• Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference  Academic Article
• Endocrine therapy: is the first generation of targeted drugs the last?  Academic Article
• Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women  Academic Article
• Endometrial Evaluation with Transvaginal US and Hysterosonography in Asymptomatic Postmenopausal Women with Breast Cancer Receiving Tamoxifen  Academic Article
• Endometrial cancer. Prevention, detection, management, and follow up.  Academic Article
• Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)  Academic Article
• Extended adjuvant therapy: the role of subset analyses  Academic Article
• Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion  Academic Article
• Functional characterization of estrogen receptor subtypes, ERα and ERβ, mediating vitellogenin production in the liver of rainbow trout  Academic Article
• HER2/neu in systemic therapy for women with breast cancer: a systematic review  Academic Article
• Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole  Academic Article
• Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.  Academic Article
• Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17  Academic Article
• Is tamoxifen effective in prevention of breast cancer?  Academic Article
• Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen  Academic Article
• Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?  Academic Article
• Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues  Academic Article
• Modulatory effects of estrogen in two murine models of experimental colitis  Academic Article
• New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17  Academic Article
• OESTROGEN MODULATORS AND CLEAR CELL CARCINOMA OF VAGINA  Academic Article
• Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle  Academic Article
• Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29  Academic Article
• Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer  Academic Article
• Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)  Academic Article
• Ovarian ablation as adjuvant therapy for early-stage breast cancer  Academic Article
• Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.  Academic Article
• Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx  Academic Article
• Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer  Academic Article
• Polychemotherapy for early breast cancer: an overview of the randomised trials  Academic Article
• Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer  Academic Article
• Postmenopausal breast cancer: is the short-term pain worth the long-term gain?  Academic Article
• Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction  Academic Article
• Preparation and Evaluation of Carborane Analogues of Tamoxifen  Academic Article
• Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model  Academic Article
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial  Academic Article
• Protein Kinase C and Oxidative Stress in an Animal Model of Mania  Academic Article
• Pulmonary lymphangiomyomatosis complicating pregnancy. A case report.  Academic Article
• Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question  Academic Article
• Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17  Academic Article
• Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14  Academic Article
• Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.  Academic Article
• Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.  Academic Article
• Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview.  Academic Article
• Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14  Academic Article
• Risk of Menopause During the First Year After Breast Cancer Diagnosis  Academic Article
• Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.  Academic Article
• Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study  Academic Article
• Sensitization of human melanoma cells by tamoxifen to apoptosis induction by pancratistatin, a nongenotoxic natural compound  Academic Article
• Should Tamoxifen Be Used to Treat Premenopausal Women with Breast Cancer?  Academic Article
• Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer  Academic Article
• Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated?  Academic Article
• Synergy of pancratistatin and tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria  Academic Article
• Synthesis of Boroxifen, A Nido-Carborane Analogue of Tamoxifen  Academic Article
• Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?  Academic Article
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy  Academic Article
• TAMOXIFEN PROPHYLAXIS  Academic Article
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015  Academic Article
• Tamoxifen Attenuates the Effects of Exogenous Glucocorticoid on Bone Formation and Growth in Piglets*  Academic Article
• Tamoxifen Derivatives for Delivery of the Antitumoral (DACH)Pt Group: Selective Synthesis by McMurry Coupling, and Biochemical Behaviour  Academic Article
• Tamoxifen May Be an Effective Adjuvant Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status  Academic Article
• Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?  Academic Article
• Tamoxifen and Hypercalcemia  Academic Article
• Tamoxifen and cancer of the endometrium.  Academic Article
• Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.  Academic Article
• Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania  Academic Article
• Tamoxifen flare - an unusual case of hypercalcaemia and transient rapidly progressive pancytopenia  Academic Article
• Tamoxifen for Breast Cancer Risk Reduction  Academic Article
• Tamoxifen therapy in premenopausal patients with metastatic breast cancer.  Academic Article
• Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review  Academic Article
• The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer  Academic Article
• The Use of Stereotactic Excisional Biopsy in the Management of Invasive Breast Cancer  Academic Article
• The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer  Academic Article
• The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review.  Academic Article
• The best use of adjuvant endocrine treatments  Conference Paper
• The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation  Academic Article
• The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures  Academic Article
• The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma  Academic Article
• The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.  Academic Article
• Thrombosis of the Cerebral Veins and Sinuses  Academic Article
• Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor  Academic Article
• Transvaginal US and Hysterosonography in Postmenopausal Women with Breast Cancer Receiving Tamoxifen: Correlation with Hysteroscopy and Pathologic Study  Academic Article
• Treatment of Advanced Breast Cancer  Academic Article
• Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 5: Selective estrogen receptor modulators and hormone replacement therapy. Proceedings of a conference. Charlottesville, Virginia, USA. September 21-23, 1997.  Conference Paper
• UTILITY OF IN VITRO TEST METHODS TO ASSESS THE ACTIVITY OF XENOESTROGENS IN FISH  Academic Article
• Ultrasonographic Assessment of Endometrial Thickness: A Review  Academic Article
• Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?  Academic Article
• Venous Thromboembolism in Malignancy and Malignancy in Venous Thromboembolism  Academic Article
• WITHDRAWN: Clomiphene or tamoxifen for idiopathic oligo/asthenospermia.  Academic Article
• o,p′-DDT induction of vitellogenesis and its inhibition by tamoxifen in Nile tilapia (Oreochromis niloticus)  Academic Article